Physician profile
Sailaja Datla
NPI 1154434975
$2,996.12
in general payments reported to CMS, 2019-2025
34 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $308 · 2021: $691 · 2022: $453 · 2023: $421 · 2024: $310 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $621.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $305.73 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $237.27 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $213.67 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $177.24 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $166.29 | 2019-2022 | |
| Exact Sciences Corporation | $120.99 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $114.40 | 2019-2022 | |
| Amarin Pharma, INC. | $96.04 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.60 | 2019-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $72.14 | 2023-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $69.68 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.64 | 2022 | |
| Acadia Pharmaceuticals INC | $61.87 | 2021-2023 | Nuplazid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.69 | 2024-2025 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $55.02 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $54.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $47.38 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $40.94 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.19 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $33.54 | 2022 | |
| Amgen INC. | $31.98 | 2025 | Repatha, Otezla |
| Aimmune Therapeutics, INC. | $30.52 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $28.05 | 2024-2025 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $23.37 | 2023 | Accrufer |
| Sanofi Pasteur INC. | $22.26 | 2022 | |
| Cashflow Solutions, LLC | $18.19 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Abbvie INC. | $17.04 | 2025 | |
| Horizon Therapeutics Plc | $16.02 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.96 | 2023 | Givlaari |
| Boston Scientific Corporation | $14.38 | 2021 | |
| Electromed, INC. | $13.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.71 | 2021 | |
| Advanced Respiratory, INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sailaja Datla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.